AVTR vs. KYMR: Avantor vs. Kymera Therapeutics Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Kymera Therapeutics (KYMR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while KYMR is classified in Biotechnology.

Company profile comparison for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Profile Item	AVTR	KYMR
Name	Avantor, Inc.	Kymera Therapeutics Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	10.48 billion USD	11.25 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 17, 2019	August 21, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

KYMR

GSPC

Avantor (AVTR) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Kymera Therapeutics (KYMR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Kymera Therapeutics (KYMR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
Total Return (1Y)	36.41%	131.52%
Total Return (3Y, Annualized)	-5.02%	111.65%
Total Return (5Y, Annualized)	-16.62%	15.68%

Risk Profile

Drawdown History

AVTR

KYMR

GSPC

Avantor (AVTR) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Kymera Therapeutics (KYMR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
Volatility (1Y, Annualized)	43.39%	62.83%
Beta (5Y)	0.94	2.00
Max Drawdown (5Y)	-82.42%	-83.27%
Avg. Volume (3M)	8.56M	833.05K

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and KYMR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
Sharpe Ratio (1Y)	0.74	2.03
Sortino Ratio (1Y)	1.17	4.16

Profitability

ROE (TTM)

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Avantor (AVTR) reports 5.91%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
KYMR: -27.29%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Avantor (AVTR) at 5.08% retains a top-quartile share of revenue as profit, ahead of Kymera Therapeutics (KYMR) at 0.00%, which keeps about the industry-typical share.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
KYMR: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Avantor (AVTR) reports 8.19%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
KYMR: -396.04%

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
ROE (TTM)	5.91%	-27.29%
ROA (TTM)	2.83%	-17.64%
Net Margin (TTM)	5.08%	0.00%
Operating Margin (TTM)	8.19%	-396.04%
Gross Margin (TTM)	31.59%	0.00%

Growth

Revenue Growth

Both Avantor (AVTR) at -3.41% and Kymera Therapeutics (KYMR) at -16.70% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
Revenue Growth (YoY)	-3.41%	-16.70%
Revenue Growth (3Y CAGR)	-4.46%	-5.74%
EPS Growth (YoY)	-175.00%	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max: 25.13
Q3: 12.13
KYMR: 11.13
Median: 5.52
Q1: 2.47
Min: 0.10

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Avantor (AVTR) at 0.63 and Kymera Therapeutics (KYMR) at 0.05 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max: 1.42
Q3: 0.65
Median: 0.15
KYMR: 0.05
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
Current Ratio (MRQ)	1.89	11.13
Debt / Equity (MRQ)	0.63	0.05
Net Debt / EBITDA	3.40	--

Dividends

Dividend Yield (TTM)

Neither Avantor (AVTR) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Avantor (AVTR) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Avantor (AVTR) trades at 30.94 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
KYMR: --

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): KYMR does not report P/E ratio, so it has no value marker; AVTR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Kymera Therapeutics (KYMR) at 110.00 prices above its industry range — a wide gap in sales valuation between them.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR: 110.00
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Avantor (AVTR) at 1.80 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max: 13.53
KYMR: 6.96
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Kymera Therapeutics (KYMR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Kymera Therapeutics (KYMR)
Metric	AVTR	KYMR
P/E Ratio (TTM)	30.94	--
P/S Ratio (TTM)	1.58	110.00
P/B Ratio (MRQ)	1.80	6.96
Free Cash Flow Yield (TTM)	4.21%	-1.46%